Skip to main content
DAEWOONG CO.,LTD logo

DAEWOONG CO.,LTD — Investor Relations & Filings

Ticker · 003090 ISIN · KR7003090008 KO Manufacturing
Open in API
Filings indexed 311 across all filing types
Latest filing 2024-03-21 Regulatory Filings
Country KR South Korea
Listing KO 003090

About DAEWOONG CO.,LTD

https://www.daewoong.co.kr

Daewoong Co., Ltd. is a holding company operating primarily in the biotechnology and healthcare sectors. Its core business, conducted through subsidiaries like Daewoong Pharmaceutical, involves the research, development, manufacturing, and commercialization of a broad range of pharmaceutical products. The company's portfolio includes prescription drugs, over-the-counter (OTC) medications, quasi-drugs, and active pharmaceutical ingredients (APIs). Daewoong focuses on developing innovative drugs, with established expertise in gastrointestinal and endocrine therapeutic areas. A key product in its global portfolio is Nabota, an FDA-approved botulinum toxin. The company emphasizes continuous R&D and engages in open collaboration to develop new healthcare solutions.

Recent filings

Filing Released Lang Actions
[기재정정]신규시설투자등(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from Daewoong regarding a 'Correction Report' (정정신고) for a 'New Facility Investment' (신규시설투자). It details changes to the investment amount for the Magok C&D Center due to rising construction and labor costs. Since this is a specific regulatory disclosure regarding capital expenditure and facility investment updates, and it does not fit into the other specific categories like M&A or share issues, it is classified as a Regulatory Filing (RNS).
2024-03-21 Korean
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a comprehensive 'Independent Auditor's Report' (연결감사보고서) for Daewoong Co., Ltd. for the fiscal year ending December 31, 2023. It includes the auditor's opinion, key audit matters, and the full set of consolidated financial statements (Statement of Financial Position, Statement of Comprehensive Income, Statement of Changes in Equity, and Statement of Cash Flows) along with detailed notes. This document represents the audited financial results for the full fiscal year, which aligns with the definition of an Annual Report (10-K) in the provided schema. FY 2023
2024-03-20 Korean
[기재정정]단일판매ㆍ공급계약체결(자회사의 주요경영사항)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a 'Single Sale/Supply Contract' (단일판매ㆍ공급계약체결) and a subsequent amendment (정정신고). It details a commercial supply agreement between Daewoong Pharmaceutical and Yangtze River Pharmaceutical. Since this is a specific regulatory disclosure of a material contract and does not fit into categories like M&A, dividends, or financial reports, it is classified as a general regulatory filing.
2024-03-14 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경(자회사의 주요경영사항)
Earnings Release Classification · 100% confidence The document is a regulatory filing from the Korean stock exchange (KRX) regarding a significant change in revenue or profit structure (30% or more) for a subsidiary (Daewoong Bio). This type of disclosure is a standard regulatory requirement for listed companies to report material financial changes. It provides specific financial data (revenue, operating profit, net income) for the current and previous fiscal years. Since it is a formal regulatory disclosure of financial results rather than a full annual report or a simple announcement of a report's availability, it falls under the 'Regulatory Filings' category. FY 2023
2024-03-08 Korean
감사보고서제출(자회사의 주요경영사항)
Audit Report / Information Classification · 100% confidence The document is a regulatory filing submitted to the Korea Exchange (KRX) titled '감사보고서 제출' (Submission of Audit Report). It provides the audit opinion (unqualified/appropriate), key financial data (assets, liabilities, equity, revenue, profit) for both consolidated and separate financial statements, and identifies the external auditor (Samjong KPMG). While it contains financial data, it is a formal regulatory disclosure of the audit report's submission rather than the full annual report (10-K) or a standalone audit report document. Given the structure and purpose of notifying the market about the audit results, it fits the 'AR' (Audit Report / Information) category as it specifically details the audit opinion and financial results derived from the audit. FY 2023
2024-03-08 Korean
감사보고서제출(자회사의 주요경영사항)
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) for Daewoong Bio. It provides the audit opinion, financial statements, and auditor information for the fiscal year 2023. While it contains financial data, it is a specific regulatory disclosure regarding the completion and submission of an audit report, which falls under the Audit Report/Information category. FY 2023
2024-03-08 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.